Company Description
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.
It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Its development portfolio focuses on central nervous system disorders. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia.
TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition.
Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA.
The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS).
Its immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.
The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox.
TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19.
Its infectious disease development portfolio also comprises TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals.
The company was founded in 2007 and is headquartered in Chatham, New Jersey.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Dr. Seth Lederman M.D. |
Contact Details
Address: 26 Main Street, Suite 101 Chatham, New Jersey 07928 United States | |
| Phone | 212-980-9155 |
| Website | tonixpharma.com |
Stock Details
| Ticker Symbol | TNXP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001430306 |
| CUSIP Number | 890260862 |
| ISIN Number | US8902608541 |
| Employer ID | 26-1434750 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Seth Lederman M.D. | Co-Founder, President, Chief Executive Officer and Chairman |
| Bradley Saenger CPA | Chief Financial Officer and Treasurer |
| Mrs. Jessica Edgar Morris | Chief Operating Officer |
| Dr. Gregory M. Sullivan M.D. | Chief Medical Officer and Secretary |
| Dr. Herbert W. Harris M.D., Ph.D. | Executive Vice President of Translational Medicine |
| Dr. Bruce L. Daugherty M.B.A., Ph.D. | Executive Vice President of Research |
| Siobhan Fogarty B.Sc., M.Sc. | Executive Vice President of Product Development |
| Dr. Darryl Rideout Ph.D. | Executive Vice President of Experimental Chemistry |
| Dr. Sina Bavari Ph.D. | Executive Vice President of Infectious Disease Research and Development |
| Dr. Zeil Rosenberg M.D., M.P.H. | Executive Vice President of Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | ARS | Filing |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 424B5 | Filing |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 8-K | Current Report |